MX2023007224A - Agonistas del receptor del polipeptido tipo glucagon 1 (glp-1) de accion prolongada y metodos de uso de los mismos. - Google Patents
Agonistas del receptor del polipeptido tipo glucagon 1 (glp-1) de accion prolongada y metodos de uso de los mismos.Info
- Publication number
- MX2023007224A MX2023007224A MX2023007224A MX2023007224A MX2023007224A MX 2023007224 A MX2023007224 A MX 2023007224A MX 2023007224 A MX2023007224 A MX 2023007224A MX 2023007224 A MX2023007224 A MX 2023007224A MX 2023007224 A MX2023007224 A MX 2023007224A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- methods
- receptor agonist
- polypeptides
- agonist polypeptides
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126736P | 2020-12-17 | 2020-12-17 | |
| PCT/US2021/063920 WO2022133148A1 (en) | 2020-12-17 | 2021-12-16 | Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007224A true MX2023007224A (es) | 2023-09-05 |
Family
ID=80123475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007224A MX2023007224A (es) | 2020-12-17 | 2021-12-16 | Agonistas del receptor del polipeptido tipo glucagon 1 (glp-1) de accion prolongada y metodos de uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12084485B2 (https=) |
| EP (1) | EP4263587A1 (https=) |
| JP (1) | JP2024502740A (https=) |
| KR (1) | KR20230156689A (https=) |
| CN (1) | CN116917311A (https=) |
| AR (1) | AR124395A1 (https=) |
| AU (1) | AU2021400738A1 (https=) |
| CA (1) | CA3202389A1 (https=) |
| IL (1) | IL303686A (https=) |
| MX (1) | MX2023007224A (https=) |
| TW (1) | TW202237628A (https=) |
| WO (1) | WO2022133148A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| IL322661A (en) * | 2023-02-10 | 2025-10-01 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and its history, composition containing them and their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2200626A4 (en) * | 2007-09-07 | 2012-02-15 | Ipsen Pharma Sas | ANALOGUE OF EXENDIN-4 AND EXENDIN-3 |
| RU2547990C2 (ru) * | 2009-09-28 | 2015-04-10 | Интарсия Терапьютикс, Инк. | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства |
| BR112014014898A2 (pt) * | 2011-12-22 | 2020-10-27 | Pfizer Inc. | processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2 |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR102574993B1 (ko) * | 2016-05-16 | 2023-09-06 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| MX2018014966A (es) * | 2016-06-09 | 2019-08-14 | Medimmune Ltd | Peptidos monolipidados resistentes a proteasas. |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
-
2021
- 2021-12-16 US US17/553,381 patent/US12084485B2/en active Active
- 2021-12-16 CA CA3202389A patent/CA3202389A1/en active Pending
- 2021-12-16 MX MX2023007224A patent/MX2023007224A/es unknown
- 2021-12-16 KR KR1020237023789A patent/KR20230156689A/ko active Pending
- 2021-12-16 JP JP2023537184A patent/JP2024502740A/ja active Pending
- 2021-12-16 AR ARP210103539A patent/AR124395A1/es unknown
- 2021-12-16 CN CN202180089098.0A patent/CN116917311A/zh active Pending
- 2021-12-16 EP EP21851897.5A patent/EP4263587A1/en not_active Withdrawn
- 2021-12-16 AU AU2021400738A patent/AU2021400738A1/en active Pending
- 2021-12-16 WO PCT/US2021/063920 patent/WO2022133148A1/en not_active Ceased
- 2021-12-16 IL IL303686A patent/IL303686A/en unknown
- 2021-12-17 TW TW110147341A patent/TW202237628A/zh unknown
-
2024
- 2024-07-22 US US18/779,857 patent/US20250034225A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230063420A1 (en) | 2023-03-02 |
| US12084485B2 (en) | 2024-09-10 |
| KR20230156689A (ko) | 2023-11-14 |
| EP4263587A1 (en) | 2023-10-25 |
| AU2021400738A1 (en) | 2023-07-13 |
| JP2024502740A (ja) | 2024-01-23 |
| CA3202389A1 (en) | 2022-06-23 |
| TW202237628A (zh) | 2022-10-01 |
| US20250034225A1 (en) | 2025-01-30 |
| AR124395A1 (es) | 2023-03-22 |
| CN116917311A (zh) | 2023-10-20 |
| IL303686A (en) | 2023-08-01 |
| WO2022133148A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007224A (es) | Agonistas del receptor del polipeptido tipo glucagon 1 (glp-1) de accion prolongada y metodos de uso de los mismos. | |
| AU2020201322B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| ES2322293T3 (es) | Agonistas de pyy y usos de los mismos. | |
| Bernichtein et al. | Development of pure prolactin receptor antagonists | |
| JP6200025B2 (ja) | 心臓病の処置 | |
| JP6391589B2 (ja) | 官能基化されたエキセンディン−４誘導体 | |
| CN105745222B (zh) | 酰化胰高血糖素类似物 | |
| AU2011247452B2 (en) | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use | |
| JP6731958B2 (ja) | 選択的ｐｙｙ化合物及びその使用 | |
| MX2022013024A (es) | Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos. | |
| US11478551B2 (en) | Long-acting adrenomedullin derivative | |
| Joshi et al. | Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance | |
| US20150376257A1 (en) | Glucagon analogues | |
| TW201202265A (en) | Glucagon analogues | |
| JP2012532898A (ja) | アシル化グルカゴン類似体 | |
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| KR20130028053A (ko) | 장기적 생체 내 효능을 갖는 성장 호르몬 | |
| US7928060B2 (en) | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them | |
| Huang et al. | Characterization of glucagon-like peptide 1 receptor (GLP1R) gene in chickens: functional analysis, tissue distribution, and identification of its transcript variants | |
| MX2022013023A (es) | Peptidos selectivos del receptor de glucagon de accion prolongada y metodos de uso. | |
| EP1325930A1 (en) | Mammal prolactin variants | |
| Niv-Spector et al. | Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist | |
| US20250326814A1 (en) | Modified oxyntomodulin and methods of use thereof | |
| Hao et al. | Expression of a recombinant bifunctional protein from a chimera of human lutropin receptor and human chorionic gonadotropin β-subunit |